Skip to main content
. 2014 Apr 14;111(17):6401–6406. doi: 10.1073/pnas.1404205111

Fig. 3.

Fig. 3.

Survival and weight changes of BALB/c mice administered Sp2CBMTD before a lethal challenge with mouse-adapted A/California/04/2009 (H1N1) influenza virus. (A) BALB/c mice (n = 5) were given single, double, or triple intranasal doses of Sp2CBMTD (50 µg) on days −7, −3, or −1 before viral challenge on day 0. Mice also were given a triple intranasal dose of Sp2CBMTD alone to determine the toxicity of the biologic (shown in blue in the right panel). (B) Survival and weight changes of mice (n = 5) after single intranasal doses of Sp2CBMTD (10, 1, or 0.1 µg) given on days −7, −3, or −1 before viral challenge. (Upper) Survival curves for each administration day. (Lower) Corresponding weight-loss curves. In all cases, control animals were infected and mock-treated with PBS only. Each value represents mean body weight ± SD for five mice. (C) Virus lung titers on days 3, 6, and 9 p.i. following intranasal administration of single dose of Sp2CBMTD on day −7, −3, or −1 before lethal viral challenge. Values represent the mean viral titers (expressed as log10 50% tissue culture infectious dose/mL) ± SD from three mice. *P < 0.001 compared with control (infected, untreated) mice.